Close Menu

NEW YORK (GenomeWeb) – Switzerland's CRISPR Therapeutics and Germany's Bayer today announced a yet unnamed joint venture to develop ways to deliver CRISPR/Cas9 genome editing in a clinical setting.

The deal brings together Bayer's experience in protein engineering and knowledge of human diseases with CRISPR Therapeutics' CRISPR/Cas9 intellectual property and genome editing expertise, the firms said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.